RK22
Novel antimicrobial peptide from Hirudinaria manillensis salivary transcriptome — MIC 6.25 µg/mL against MRSA, no thrombogenic effect, in vivo efficacy in mice.
- Hementerin80 kDa
- Hementin80 kDa
- Hementin-Like Protein (HLP-1)80 kDa
- Leech Collagenase70 kDa
- Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
- Leech Apyrase67 kDa
- Calin65 kDa
- Hyaluronidase60 kDa
- Antithrombin III binding protein58 kDa
- Collagenolytic Fibrinolysin55 kDa
- Leech Thrombospondin-Like Protein50 kDa
- RK222.7 kDa
Mechanistic Evidence Box
Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.- Page type
- Compound profile
- Evidence type
- Preclinical / biochemical characterization
- Evidence level
- Preclinical (animal)
- Drug vs leech
- Purified natural compound
- Safety domains
- Antibiotic stewardship
Clinical translation limit
RK22's in vitro and murine antibacterial activity does NOT establish clinical efficacy in humans. No FDA-approved derivative exists; H. manillensis is not the FDA-cleared K040187 medicinal leech species.
Molecular Profile
- Category
- Antimicrobial
- Evidence tier
- Preclinical
- Molecular weight
- 2,700 Da
- Source species
- Hirudinaria manillensis
- Discovered
- 2023 · Lu X et al.
Biological Targets
- → Methicillin-resistant Staphylococcus aureus (MRSA)
- → Staphylococcus biofilm
Key Citations
- Lu X et al. (2023), Int J Mol Sci · PMID 37686259
External Resources
Related Antimicrobial Compounds
Theromacin
Cationic, cysteine-rich antimicrobial peptide (75 amino acids) active against Gram-positive bacteria — part of the leech's innate immunity.
Theromyzin
Linear anionic antimicrobial peptide (86 amino acids) active against Gram-positive bacteria — the first anionic antimicrobial peptide described in invertebrates.
Macrostomin
Antimicrobial peptide active against Gram-positive bacteria — amphipathic alpha-helix.
Hirunipins
Newly-characterized antimicrobial peptide family (Kumar 2025) — candidate next-generation antibiotics against AMR pathogens.